Nurtec and Ubrelvy Are NOT Approved for Children
Neither Nurtec (rimegepant) nor Ubrelvy (ubrogepant) should be used in children, as both medications explicitly state in their FDA labeling that safety and effectiveness have not been established in pediatric patients. 1, 2
FDA-Approved Indications
Both medications are FDA-approved only for adults:
- Nurtec ODT (rimegepant): Approved for acute treatment of migraine attacks and preventive treatment of episodic migraine in adults 1
- Ubrelvy (ubrogepant): Approved for acute treatment of migraine attacks in adults 2
The FDA drug labels for both medications clearly state: "It is not known if [Nurtec/Ubrelvy] is safe and effective in children." 1, 2
Current Evidence in Pediatric Populations
Rimegepant (Nurtec)
While there is emerging research, it remains investigational:
- A 2026 Phase 1 study evaluated weight-adjusted dosing (25-75 mg based on body weight) in children aged 6-12 years with migraine history 3
- The study found favorable safety in 21 children, but exposures were lower than adults in children weighing ≤50 kg, indicating current dosing may be suboptimal 3
- A retrospective analysis of 12 adolescents (mean age 15.3 years) showed 83% reported improvement with off-label use, with no adverse events 4
- These findings require further refinement and prospective trials before clinical use can be recommended 3
Ubrogepant (Ubrelvy)
No pediatric studies were identified in the provided evidence.
Clinical Guidance
The 2025 American College of Physicians guideline for acute migraine treatment applies only to nonpregnant adults and explicitly excludes pediatric populations 5. The guideline positions gepants (rimegepant, ubrogepant, zavegepant) as options for adults who fail combination therapy with triptans plus NSAIDs or acetaminophen 5.
For Pediatric Migraine Management
Until FDA approval is obtained for pediatric use:
- Use age-appropriate acute migraine treatments (NSAIDs, acetaminophen, triptans approved for adolescents)
- Consider enrollment in clinical trials if available
- Do not use gepants off-label in children outside of research settings given the lack of established safety, efficacy, and appropriate dosing
Important Caveat
While retrospective data suggests potential tolerability in adolescents 4, pharmacokinetic studies demonstrate inadequate drug exposure in children under 50 kg with current dosing strategies 3. This means even if prescribed off-label, the medication may not work effectively in younger or smaller children, and optimal dosing remains unknown.